- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04860895
Detection of SARS-CoV-2 in Nasopharyngeal Swabs by Using Multi-Spectral Screening System
The Reliability of the Computer Aided Multi-Spectral Screening System In the Diagnosis of Covid-19
Studieöversikt
Detaljerad beskrivning
The primary purpose of this study is to test whether artificial intelligence (AI) will identify existing SARS-COV-2 in nasopharyngeal swab samples using multi-spectral screening technology..
Multi spectral screening testing device called AP-23 offers a non-invasive system for the diagnosis of SARS-COV-2 as a solution. This approach makes multi-spectral diagnostic methods suitable for use by any end user and allows the establishment of Internet of Things systems.
COVID-19 contagion, which began in the northern hemisphere, continues to affect human health and the world economy in tremendously. Early diagnosis of the disease and, accordingly, the breaking of the transmission chain through filiation studies is very important for public health until an effective and safe vaccine is found. PCR tests, which we currently use as the gold standard to prove the existence of the virus, have not been sufficient to prevent the pandemic for the following reasons;
- PCR tests should be performed in a hospital or clinical setting
- There is a need for a custom kit
- There is a need for trained individuals to perform the test
- Standardization is not ensured for the receipt of test sample
- With at least 30 minutes for receipt of the test results, it takes up to 3-day
- testing is expensive and is usually applied to people who have symptoms and thus asymptomatic carriers are missed.
The primary purpose of this study is to test whether SARS-COV-2 can be detected in nasopharyngeal swab samples using multi-spectral screening technology. Multi-spectral techniques are based on phenomena related to absorption, excitation and propagation of biomolecules. In short, by irradiating the sample with electromagnetic energy, some molecules absorb and re-emit less energetic radiation. This phenomenon is called radiation, and the radiated spectrum is a function of certain molecules that combine microorganisms / viruses.
At this point, FableCorp's AP-23 system uses data from a minimally invasive or non-invasive simple measurement based on multi-spectral screening technology to calculate the presence or concentration of the desired product in a biological liquid as the solution to be used.
The most unique approach of the FableCorp system, is to use the A.I. to detect the desired biochemical / cell / virus is to scan appropriate multi-spectral inputs. Data mining tools, where it simultaneously eliminates noise in raw data generated from various multi-spectral spectroscopy inputs, give very clear results. This approach makes multi-spectral technology suitable for use as point-of-care systems for any end user, and also leads to the realization of full automation (Internet of Things) systems.
A.I. the base solution for Pointer signal detection / processing eliminates biochemical additives (kits) and specialized personnel.
AI's evaluation of data takes place within 15-30 seconds. If the effectiveness of this application is proven in the diagnosis of SARS-COV-2, many more people will be able to be screened in a much faster time, much cheaper, and filiation will be applied to the necessary people much faster.
Study Design Stage 1: Nasopharyngeal samples taken from COVID-19 suspected individuals will be given to artificial intelligence to learn positive and negative cases, and the learning results will be calculated as the learning accuracy for negative and positive samples. (n=4000, 2000 positive and 2000 negative)
Stage 1, Output Parameters (Evaluation of Learning Performance of Artificial Intelligence):
PCR results and AP-23 results obtained as a result of comparison; PCR Accordance, PCR Accordance for Negative Samples, PCR Accordance for Positive Samples.
Stage 2: Based on the Artificial Intelligence Learning accuracy rate second stage of the study will be initiated. At this stage, Nasopharyngeal swab samples will be tested by PCR, AP-23, and the results will be tested and be compared and the sensitivity of detection compared with results obtained by (n=400, 200 positive and 200 negative)
Stage 2, Output Parameters (Evaluation of Test Performance of Artificial Intelligence):
Nasopharyngeal swab obtained by comparison with PCR and AP-23 results in samples; Sensitivity, Specificity, Negative Prediction Value, Positive Prediction Value.
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Deniz Unver, MSc.
- Telefonnummer: +905380246808
- E-post: deniz.unver@fablecorp.com
Studera Kontakt Backup
- Namn: Emre Günerken
- Telefonnummer: 905360300713
- E-post: emre.gunerken@fablecorp.com
Studieorter
-
-
Istanbul
-
Sancaktepe, Istanbul, Kalkon, 34785
- Rekrytering
- Sancaktepe Sehit Prof.Dr. Ilhan Varank Training and Research Hospital
-
Kontakt:
- İsmail Tayfur, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
All people who applied to hospitals with suspicion of COVID-19
Exclusion Criteria:
Person who cannot give nasopharyngeal samples
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Övrig: Nasopharyngeal swabs
Nasopharyngeal swabs samples of volunteers who is referred with suspicion of Covid19.
|
AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Assessment of AI's Learning Performance:
Tidsram: 2 MONTHS
|
Compared PCR results with AP-23 results; PCR Accordance, PCR Accordance for Negative Samples, PCR Accordance for Positive Samples.
|
2 MONTHS
|
Evaluation of Artificial Intelligence's Test Performance)
Tidsram: 1 MONTH
|
As a result of comparison with the PCR and AP-23 results in nasopharyngeal swab samples; Sensitiviy, Specificity, Negative Prediction Value, Positive Prediction Value
|
1 MONTH
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: İsmail Tayfur, MD, Sancaktepe Sehit Prof.Dr. Ilhan Varank Training and Research Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SNCKTP_AP-23
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Covid19
-
Henry Ford Health SystemAvslutad
-
Ricardo Pereira MestreInstitute of Oncology Research (IOR); Istituto Cantonale di PatologiaAvslutad
-
Instituto de Investigación Hospital Universitario...Instituto de Salud Carlos III; Spanish Clinical Research Network - SCReNAktiv, inte rekryterande
-
Inmunova S.A.Hospital Italiano de Buenos Aires; Laboratorio Elea Phoenix S.A.; Hospital... och andra samarbetspartnersAvslutad
-
Manchester University NHS Foundation TrustUniversity of ManchesterAvslutad
-
Rush University Medical CenterHospital Civil de GuadalajaraAvslutadCovid19Förenta staterna, Mexiko
-
Evelyne D.TrottierAvslutad
-
Sinovac Research and Development Co., Ltd.Avslutad
-
Mabwell (Shanghai) Bioscience Co., Ltd.Shanghai Public Health Clinical CenterAvslutad
-
Erasmus Medical CenterUniversity Medical Center Groningen; Academisch Medisch Centrum - Universiteit... och andra samarbetspartnersRekrytering
Kliniska prövningar på AP-23
-
Universidad Rey Juan CarlosAvslutadArtros, knä | Muskuloskeletala manipulationerSpanien
-
University of Applied Sciences of Western SwitzerlandUniversity Hospital, Geneva; University of Lausanne Hospitals; Hôpital Fribourgeois och andra samarbetspartnersAvslutadKroniska njursjukdomar | Dialys | Kroniska njursjukdomar associerad pruritusSchweiz
-
Sameek RoychowdhuryNational Cancer Institute (NCI)IndragenLokalt avancerad malignt fast neoplasma | Metastatisk malign fast neoplasma | ALK genmutation | Metastatisk malign neoplasm i hjärnan | Avancerad malign neoplasm | ALK Fusion Protein Expression | Metastatisk malign neoplasma i centrala nervsystemet | ROS1 genmutation | ALK-genförstärkning | ROS1 Fusion Positiv och andra villkorFörenta staterna
-
AL-S PharmaOkändAmyotrofisk lateral sklerosKanada
-
Apollo Endosurgery, Inc.AvslutadFetmaStorbritannien, Australien, Förenta staterna, Italien, Kanada, Belgien
-
AL-S PharmaAktiv, inte rekryterandeAmyotrofisk lateral sklerosTyskland, Korea, Republiken av, Förenta staterna, Belgien, Kanada, Sverige
-
Yonsei UniversityAvslutadStroke | Hemiplegisk gångKorea, Republiken av
-
AM-PharmaAvslutadSepsis | Bakteriella infektioner och mykoserNederländerna, Belgien
-
Algiax Pharmaceuticals GmbHFGK Clinical Research GmbHRekryteringPerifer postkirurgisk neuropatisk smärtaTjeckien, Tyskland, Spanien, Belgien, Frankrike